How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
23
KMTS Quote, Financials, Valuation and Earnings
Last price:
$24.68
Seasonality move
:
--
Day range:
$24.03 - $25.65
52-week range:
$13.25 - $30.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
17.06x
P/B ratio:
7.16x
Volume:
253.3K
Avg. volume:
280.3K
1-year change:
--
Market cap:
$1.2B
Revenue:
$59.8M
EPS (TTM):
-$2.68
Analysts' Opinion
-
Consensus RatingKestra Medical Technologies Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $29.00, Kestra Medical Technologies Ltd. has an estimated upside of 17.55% from its current price of $24.67.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $24.00 representing 100% downside risk from its current price of $24.67.
Fair Value
-
According to the consensus of 6 analysts, Kestra Medical Technologies Ltd. has 17.55% upside to fair value with a price target of $29.00 per share.
KMTS vs. S&P 500
-
Over the past 5 trading days, Kestra Medical Technologies Ltd. has underperformed the S&P 500 by -0.05% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Kestra Medical Technologies Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kestra Medical Technologies Ltd. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Kestra Medical Technologies Ltd. reported revenues of $22.6M.
Earnings Growth
-
Kestra Medical Technologies Ltd. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Kestra Medical Technologies Ltd. reported earnings per share of -$0.64.
Enterprise value:
1B
EV / Invested capital:
--
Price / LTM sales:
17.06x
EV / EBIT:
--
EV / Revenue:
14.07x
PEG ratio (5yr expected):
-0.22x
EV / Free cash flow:
-9.12x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$34.5M
Return On Assets:
-63.04%
Net Income Margin (TTM):
-177.06%
Return On Equity:
-105.99%
Return On Invested Capital:
-77.65%
Operating Margin:
-140.73%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-10-31 | 2024-10-31 | 2025-10-31 | 2024-10-31 | 2025-10-31 | |
| Income Statement | ||||||
| Revenue | -- | $45.8M | $74.3M | $14.7M | $22.6M | |
| Gross Profit | -$1.9M | $12.3M | $34.5M | $5.8M | $11.4M | |
| Operating Income | -- | -$77.9M | -$129.4M | -$19.1M | -$31.8M | |
| EBITDA | -- | -$35.8M | -$121.3M | -$17.3M | -$29.4M | |
| Diluted EPS | -$1.07 | -$1.89 | -$2.68 | -$0.48 | -$0.64 | |
| Period Ending | 2021-10-31 | 2022-10-31 | 2023-10-31 | 2024-10-31 | 2025-10-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $87.9M | $195.4M | |
| Total Assets | -- | -- | -- | $126.1M | $246.7M | |
| Current Liabilities | -- | -- | -- | $31.3M | $35.8M | |
| Total Liabilities | -- | -- | -- | $82.1M | $82.6M | |
| Total Equity | -- | -- | -- | $44M | $164.1M | |
| Total Debt | -- | -- | -- | $46.1M | $44.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-10-31 | 2024-10-31 | 2025-10-31 | 2024-10-31 | 2025-10-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$66.3M | -$86.7M | -$18M | -$18.3M | |
| Cash From Investing | -- | -$20.6M | -$10.4M | -$21.6M | -$7.4M | |
| Cash From Financing | -- | $139.8M | $195.6M | $16.5M | -$27K | |
| Free Cash Flow | -- | -$86.9M | -$114.6M | -$22.5M | -$25.8M | |
KMTS
Sector
Market Cap
$1.2B
--
Price % of 52-Week High
82.23%
--
Dividend Yield
0%
--
Shareholder Yield
-15.68%
--
1-Year Price Total Return
--
--
Beta (5-Year)
--
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$24.79
200-day SMA
Buy
Level
$21.97
Bollinger Bands (100)
Sell
Level
22.87 - 27.05
Chaikin Money Flow
Sell
Level
-34.2K
20-day SMA
Buy
Level
$24.45
Relative Strength Index (RSI14)
Sell
Level
48.92
ADX Line
Sell
Level
11.72
Williams %R
Neutral
Level
-29.7872
50-day SMA
Sell
Level
$25.41
MACD (12, 26)
Buy
Level
3.50
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Sell
Level
-422.1K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.0491)
Sell
CA Score
(Annual)
Level (-3.0997)
Sell
Beneish M-Score
(Annual)
Level (-1.7818)
--
Momentum Score
Level (--)
Sell
Ohlson Score
Level (2.5512)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kestra Medical Technologies Ltd. is a commercial-stage, wearable medical device and digital healthcare company. It focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company was founded by Brian Webster and Traci S. Umberger in 2014 and is headquartered in Kirkland, WA.
Stock Forecast FAQ
In the current month, KMTS has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The KMTS average analyst price target in the past 3 months is $29.00.
-
Where Will Kestra Medical Technologies Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kestra Medical Technologies Ltd. share price will rise to $29.00 per share over the next 12 months.
-
What Do Analysts Say About Kestra Medical Technologies Ltd.?
Analysts are divided on their view about Kestra Medical Technologies Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kestra Medical Technologies Ltd. is a Sell and believe this share price will drop from its current level to $24.00.
-
What Is Kestra Medical Technologies Ltd.'s Price Target?
The price target for Kestra Medical Technologies Ltd. over the next 1-year time period is forecast to be $29.00 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is KMTS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kestra Medical Technologies Ltd. is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KMTS?
You can purchase shares of Kestra Medical Technologies Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kestra Medical Technologies Ltd. shares.
-
What Is The Kestra Medical Technologies Ltd. Share Price Today?
Kestra Medical Technologies Ltd. was last trading at $24.68 per share. This represents the most recent stock quote for Kestra Medical Technologies Ltd.. Yesterday, Kestra Medical Technologies Ltd. closed at $24.67 per share.
-
How To Buy Kestra Medical Technologies Ltd. Stock Online?
In order to purchase Kestra Medical Technologies Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get KMTS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KMTS
Sector
P/E ratio
--
--
PEG ratio
-0.22x
--
P/B ratio
7.16x
--
Price / LTM sales
17.06x
--
Growth Metrics
KMTS
Sector
Revenue growth
53.4%
--
Earnings growth
-33.41%
--
Revenue (5-year growth)
--
--
Earnings forecast
-$0.60
--
Profitability
KMTS
Sector
Profitability FY 2025
$24.2M
--
Return on invested capital
-77.65%
--
Return on assets
-63.04%
--
Return on equity
-105.99%
--
Earnings Date
Last Earnings Date
Dec
11
Next Earnings Date
Mar
17
Estimated Next Earnings Date
Mar
12
Balance Sheet
KMTS
Sector
Total cash
$175.4M
--
Short term investments
--
--
Total assets
$295.7M
--
Long term debt
$44.7M
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
